ROGERS VERNON sold $847K of AEHR

ROGERS VERNON (Exec VP of Sales & Mktg.) sold 5,994 shares of AEHR TEST SYSTEMS (AEHR) at an average of $141.34 ($134.00–$143.77, $0.85M total) across 3 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · ROGERS VERNON
Published Aug 18, 2026, 5:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 6:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

This is a primary-source disclosure of an open-market sale totaling 5,994 shares at a weighted average price of $141.3442, leaving 186,232 shares after the transaction.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without other company-specific catalysts.

03

What to watch

Insider sales often reflect diversification or tax planning; without additional context (e.g., earnings, guidance, or a concurrent company catalyst), traders should avoid over-weighting the signal.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by Rogers Vernon (Exec VP of Sales & Mktg).

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR insider sale: Exec VP of Sales & Mktg Rogers Vernon sold $847,217 of AEHR shares via open-market transactions (Form 4).

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows a direct sale totaling $847k across three trades, with no 10b5-1 plan stated. Insider sales can be routine (tax/portfolio), so directional price impact is usually modest without accompanying company news.

Market effects

No sector-wide signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as less “scheduled,” but the sale size ($847k) is still small relative to typical institutional flows, limiting price impact.

Key entities

  • AEHR

    AEHR Test Systems, the company whose shares were sold by an executive insider.

  • Rogers Vernon

    Exec VP of Sales & Mktg who sold AEHR shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.